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Introduction: Lung cancer is the most malignant cancer today. Doxorubicin, an 
anthracycline antibiotic, is a widely used antineoplastic agent. Despite the good 
efficacy of doxorubicin, cardiotoxicity is the serious side effect that follows the 
treatment. Additionally, anthracyclines are likely to cause alopecia and 
myelosuppression and oral ulcerations. This toxicity and non-specific distribution of 
the drug often results in chemotherapeutic failure. The focus should be made on 
efforts to kill cancer cells by more specific targeting while sparing normal cells. 
Solid lipid nanoparticle (SLN) delivery strategies of doxorubicin have been 
developed to minimize the exposure of drug to the normal tissues. 
Methods and Results: SLNs were prepared by the modified high shear 
homogenization (HSH) method. Lipid matrix was melted and doxorubicin was 
added to obtain a clear melting solution. After, double distilled water was heated. 
surfactant was added to the water. Next, the aqueous surfactant solution was added 
to the melted lipid. Then, the hot water-surfactants solution was poured into the hot 
lipid phase, and the HSH method was employed to produce the nanoemulsion, then 
cooled under the room temperature to obtain the SLNs. 
Doxorubicin loaded SLNs were prepared with a mean size of 210 nm, doxorubicin 
encapsulation of 71% and yield of 68%. higher release rate of doxorubicin was 
achieved at lower pH, with the present system. Because of the basic nature of 
doxorubicin (pKa = 8.3), it has higher solubility at lower pH. 
Conclusions: 
These SLNs had superior in vitro anti proliferation activity against the A549 cell 
line. Doxorubicin loaded SLNs in comparison with free drug exhibits better 
selectivity for target cells and the formulation was less toxic to normal lung cells 
than against malignant A549 cells. These observations suggest that present system 
offers an exciting mode of delivery to the lipophilic anticancer drugs. 
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